Alzheimer Disease/Dementia

 
Plasma Biomarkers Achieve High Accuracy for Confirmatory Aβ Positivity in Eligibility Test for DMT in Alzheimer Disease
October 21, 2025

Plasma assays combining p-tau217 and Aβ42/40 accurately confirm AD, supporting patient eligibility for anti-amyloid disease-modifying therapies.

Benzodiazepine, Antipsychotic Use Linked to Increased Mortality in Hospice Patients With Dementia
October 15, 2025

A study reveals that starting benzodiazepines or antipsychotics in hospice patients with dementia significantly increases 180-day mortality, urging careful prescribing.

Long-Term Smoking Cessation Slows Cognitive Decline in Middle-Aged and Older Adults
October 14, 2025

An 18-year multicohort study found that smokers who quit even in later life showed 20% slower memory decline vs those who continued to smoke.

FDA Clears First Blood Test to Rule Out Alzheimer-Related Pathology in Primary Care
October 13, 2025

Roche's Elecsys pTau181 test has a 97.9% negative predictive value to rule out amyloid pathology, which will improve referral decisions and expedite treatment.

The Expanding Role of Family Medicine in Alzheimer Disease and Other Dementias
October 07, 2025

As dementia care grows more complex and more promising, the role for front-line clinicians is becoming more nuanced and more essential.

Precision Medicine Protocol for Cognitive Decline Also Reduces Depression, New Data Suggest
October 03, 2025

The ReCODE program targets metabolic, infectious, immune, vascular, and toxic exposures, elements that underlie both mood and cognition, study authors said.

FDA Grants Fast Track Designation to Anti-MTBR Tau Antibody BMS-986446 for Alzheimer Disease
October 01, 2025

The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.

Donanemab (Kisunla) Authorized in Europe for Early Symptomatic Alzheimer Disease
September 29, 2025

The European Commission granted marketing authorization for the Lilly mAb based on data from the phase 3 TRAILBLAZER-ALZ 2 and 6 clinical trials.

Alcohol Use at Any Level Linked to Higher Dementia Risk, Large Study Finds
September 24, 2025

A study of more than 559 000 adults and 2.4 million genetic samples found that alcohol consumption of any amount increases dementia risk, challenging prior evidence of protective effects from light drinking.

Emerging Tau-Targeting Antibody for Alzheimer Disease Receives FDA Fast Track Designation
September 23, 2025

FDA grants Fast Track designation to etalanetug, a promising tau-targeting antibody for Alzheimer disease that could expand treatment options for the neurodegenerative disease.